Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

PsychoGenics’ SmartCube prompts a reevaluation of CNS drug discovery

By Brian Buntz | May 22, 2023

SmartCube

SmartCube integrates behavioral neurobiology, robotics and computer vision to process and analyze large temporal and vector-based datasets. This platform uses proprietary bioinformatics and probabilistic causal inference algorithms to explore compounds’ potential to treat psychiatric disorders. [Image courtesy of PsychoGenics]

In an era of rapid AI progress, the quest to pioneer the first AI-developed drug candidates has led to an increasing number of these drug candidates entering clinical trials. One contender is ulotaront, an antipsychotic drug, that fared well in a phase 3 schizophrenia study published in NEJM in 2020. Sunovion discovered the drug in collaboration with the preclinical CRO Psychogenics. Sunovion is now developing it in clinical trials. The trace amine-associated receptor 1 agonist has entered phase 2/3 studies to test its potential in generalized anxiety disorder and as an adjunctive therapy for major depressive disorder treatment.

“Not only is this the first drug discovered using machine learning that’s this close to market, but also a proof of the potential of a polypharmacology approach for complex diseases like central nervous system (CNS) disorders,” said Daniela Brunner, the chief innovation officer of PsychoGenics.

Moving beyond the AI hype

Despite the surrounding hype, AI projects in drug development are rapidly maturing, becoming “extremely interesting” when applied to specific challenges, as Brunner pointed out.

PsychoGenics is exploring the use of machine learning across multiple domains. For starters, it aids in designing their compound libraries. “With billions of purchasable compounds available, we need to select those which will be most beneficial for our in vivo studies,” Brunner said. “Machine learning helps us narrow down these choices, selecting compounds that fall within certain parameters based on their expected activity in the SmartCube system.”

SmartCube is a platform PsychoGenics developed for phenotypic drug discovery for CNS disorders. It provides an unbiased, mechanism-agnostic method to screen compound libraries. The platform, combining custom hardware with an automated testing sequence, presents challenges to a mouse to capture more than half a million data points per mouse per session. The system compares the resulting massive dataset to a proprietary reference database to gauge the potential of compounds to treat psychiatric disorders at the drug class and subclass level.

The Star Trek inspiration behind SmartCube

Daniela Brunner

Daniela Brunner, Ph.D.

Star Trek partially inspired SmartCube, Brunner shared humorously. “We were thinking, if we could follow the mouse around and see everything that mouse does, we will be able to tell whether the mouse we just injected got an antidepressant or an anxiolytic,” she said.

In Star Trek, the cast used futuristic sensors and scanning devices to gain information about unknown objects or lifeforms. Similarly, PsychoGenics aimed to use sensors to characterize every single movement of rodents.

This led to the concept of SmartCube, which Brunner describes as a robot. “In essence, we’ve created a robot where the mouse is placed inside,” she said. “Our team of robotic engineers crafted this system to meticulously track the mouse’s every movement, capturing an immense amount of data,” she added. “By putting the animal inside, we can track everything.”

Labeling drugs: Antidepressants, anxiolytics and beyond

A key question that arose was about the data to be collected. Brunner explained, “We targeted labeled data, drawn specifically from effective human antidepressants. This label, derived from human trials, characterizes the unique behavioral signatures observed in the mouse.”

She emphasized the perspective toward studying the mice. “We don’t pretend that the mice are depressed or schizophrenic,” Brunner said. “We’re emphasizing that a mouse is a complex mammal. When a drug interacts with its diverse array of receptors, it creates a unique behavioral pattern, which we refer to as, say, an antidepressant signature.”

The process results in a kind of back-translation from humans to mice. “Our labels originate from human trials, while the data is collected from mice. We hope that this can be forward-translated when we test another drug,” Brunner said.

When using the SmartCube, the company has the option to select either commercially available compounds or generate completely new molecules based on what it has learned from SmartCube experiments.

PsychoGenics uses machine learning within the SmartCube to convert video footage of mice into numerical data for analysis.

Computer vision, a subset of machine learning, assists in the conversion. Brunner highlighted the improvements in computer vision stemming from deep learning, enabling it to identify specific mouse behaviors. “Computer vision has been around for more than 30 years,” Brunner said. “It is much, much more powerful than what it was before.” Whereas in the past, a simple computer vision system might track a mouse’s movement, current computer vision systems can identify specific mouse behaviors.

Additionally, PsychoGenics employs another layer of machine learning to train algorithms for recognizing specific behavioral signatures related to different drug types. “Machine learning plays a crucial role at every stage of our process — from selecting and creating compounds, to interpreting and analyzing the data,” Brunner said.

The SmartCube loop and continuous refinement in drug development

The SmartCube system facilitates a seamless transition from data to drugs. It comprises an iterative loop of drug testing, data collection, machine learning analysis and drug optimization. “This process continually refines the drug candidates, guided by clear behavioral signatures, and continually validated in in vivo conditions,” Brunner said.

In addition to SmartCube, PsychoGenics has developed a computer vision system to spot changes in gait geometry known as NeuroCube. A system known as PhenoCube provides an environment to evaluate disease models or treatments over an extended period. Finally, PsychoGenics’ eCube system is an EEG-based discovery platform for exploring the effects of compounds from various drug classes on electrical brain activity.

Brunner sees the role of such systems as a harbinger of the future. Referring to SmartCube’s role in developing ulotaront as an example, Brunner predicts, “We’re about to witness not just the launch of the first drug developed with machine learning, but also a demonstration of the effectiveness of a polypharmacology strategy in treating complex central nervous system disorders.”


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, machine learning and AI, Neurological Disease, Women in Pharma and Biotech
Tagged With: Antipsychotic Drugs, artificial intelligence, clinical trials, drug discovery, machine learning, Neurological Disease, Phenotypic Screening
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

The AI Meets Life Sci podcast with Kayleen Brown and Brian Buntz explores AI's role in healthcare, pharmaceuticals, biotech, medtech and more.
When will drug development have its ChatGPT moment? Inside ambitious AI initiatives at Sanofi and Medable
squirrel in the grass
Fauna Bio CEO on tapping extreme mammals for human disease breakthroughs
ATOMIC
Inside Amgen’s ATOMIC strategy to use ML to accelerate clinical trials
Caribou Biosciences
Caribou Biosciences’ CEO discusses CRISPR progress, future goals, and gender equality in biotech
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE